Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS)-Reference-Cited by-同舟云学术

Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS)

Published:2022-07-01 Issue:4 Volume:44 Page:993-1003
ISSN:2210-7703
Container-title:International Journal of Clinical Pharmacy
language:en
Short-container-title:Int J Clin Pharm

Author:

Huang Jing,Zhao Yibei,Cao Yanni,Zhang Qingxia,Ran Dongzhi,Li Jinyan,Luo Ling,Qiu Feng,Meng Long

Funder

Chongqing Health Commission

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy

Link

https://link.springer.com/content/pdf/10.1007/s11096-022-01425-4.pdf

Reference31 articles.

1. Barreca A, Lasorsa E, Riera L, et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol. 2011;47(1):R11–23.

2. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105–11.

3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.

4. Khan M, Lin J, Liao G, et al. ALK Inhibitors in the treatment of ALK positive NSCLC. Front Oncol. 2018;8:557.

5. Wang L, Wang W. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer. Oncol Rep. 2021.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capecitabine-associated gastrointestinal ulceration, haemorrhage, and obstruction: a pharmacovigilance analysis based on the FAERS;Frontiers in Pharmacology;2024-06-14

2. Relationship between Anaplastic Lymphoma Kinase (ALK) Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study.;Oncology;2024-05-20

3. Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system;International Journal of Clinical Pharmacy;2024-01-20

4. Drug-Induced Liver Injury Associated with Alk Inhibitors: A Pharmacovigilance Analysis of the Fda Adverse Event Reporting System (Faers);2024

5. Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022;BMC Pharmacology and Toxicology;2023-12-04